Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03354286
Other study ID # 43167
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 7, 2017
Est. completion date March 18, 2019

Study information

Verified date September 2019
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine the impact of a closed-loop insulin delivery system intervention on health and psychological outcomes in families with young children with Type 1 Diabetes (T1D).


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date March 18, 2019
Est. primary completion date March 18, 2019
Accepts healthy volunteers No
Gender All
Age group 2 Years to 6 Years
Eligibility To be eligible for the study, a child must meet the following criteria since enrollment in the CEP 302 Trial:

1. Diagnosis of type 1 diabetes according to ADA diagnostic criteria

2. Time since diagnosis of at least six months

3. Age between 2.00 and 6.99 years at enrollment

4. Parental consent to participate in the study

5. Completion of the CEP 302 Trial and in the continuation phase of the Medtronic CEP 302 Trial using the Medtronic MiniMed 670G pump with Enlite3 sensor.

To be eligible for the study, a parent must meet the following criteria:

1. Parent or legal guardian of a child with type 1 diabetes meeting the "child" criteria outlined above.

2. Age of 18.0 years or older.

3. Parent comprehends written English.

4. Parent understands the study protocol and signs the informed consent document.

The presence of any of the following is an exclusion for the study (since enrollment in the CEP 302 Trial):

1. Child has a medical disorder that in the judgment of the investigator will interfere with completion of any aspect of the protocol (e.g., pregnancy, kidney disease, adrenal insufficiency, skin condition that may hinder sensor application).

2. Child has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol

3. Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study

4. Child is unable to completely avoid acetaminophen for duration of study

Study Design


Intervention

Behavioral:
Developmental & Technological Demands
Education and training related to use of CGM in this age group
Distress Reduction
Education and training on reducing distress
Nutrition, Set Point, & C:I Ratio
Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
Hypoglycemia management
Education and training on reducing worries of hypoglycemia
Minimal Intervention
Minimal intervention to simulate standard care - serves as the control group

Locations

Country Name City State
United States Stanford University School of Medicine Palo Alto California

Sponsors (5)

Lead Sponsor Collaborator
Stanford University Indiana University, University of Colorado, Denver, University of South Florida, Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time spent in blood glucose range Increasingly it is recognized that the percent time spent in a target blood glucose range, which is set by the American Diabetes Association, is an important outcome. This measure will be used as a primary outcome and derived from objective data downloads. Change over 3 months
Secondary Hemoglobin A1c The hemoglobin A1c value is a biologic measure of the glycemia that is the gold standard measure of "control" of diabetes. Collected through a blood sample. Change over 3 months
Secondary Problem Areas in Diabetes This measure captures areas that are reported as problems for people with diabetes. Participants in the study report on daily problems with diabetes via this measure. Change over 3 months
Secondary Parent Diabetes Distress Scale This measure is widely used to capture the psychological distress experienced in relation to diabetes. Change over 3 months
Secondary Patient Health Questionnaire 8 This is a widely used measure that captures depressive symptoms. It is reported by the participants. Change over 3 months
Secondary State-Trait Anxiety Inventory This is a widely used measure of anxiety symptoms. It is reported by the participant. Change over 3 months
Secondary Pittsburgh Sleep Quality Index This questionnaire measures the degree to which sleep is disrupted and the quality of sleep experienced by participants. Change over 3 months
Secondary Hypoglycemic Fear Survey - Parents People with diabetes worry about hypoglycemia. This measure captures those worries and is reported by participants. Change over 3 months
Secondary Hypoglycemia Confidence Questionnaire Hypoglycemia needs to be managed in various daily situations. This questionnaire captures confidence of the participants in those various situations. Change over 3 months
Secondary Pediatric Quality of Life Inventory This is a measure of health-related quality of life. It is used to understand the broader impact on quality of life which includes social, psychological, and health aspects of daily living. Change over 3 months
Secondary Glucose Monitoring System Satisfaction Survey This a measure used to capture overall satisfaction with glucose monitoring devices used by participants. Change over 3 months
Secondary General and diabetes-specific technology use This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices. Change over 3 months
Secondary Diabetes management behaviors Amount of time spent in Auto Mode; blood glucose monitoring frequency (by meter download); adherence to pump boluses. It is objectively reported by device downloads. Change over 3 months
Secondary Health care utilization Number of visits and calls to the diabetes care team. Change over 3 months
See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Completed NCT02596204 - Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring N/A
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Completed NCT02562313 - A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog® Phase 1